Clinical trials: Migraine, Acute, open to volunteers
Acute Migraine
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
This is a long-term safety study to evaluate the safety and tolerability of intermittent use of elismetrep in the acute treatment of migraine attacks.
- Trial name
- NCT07674654
- Testing
- Elismetrep
- Where
- 113 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- TriGemX Bio, Inc.
Acute Headache, Migraine
High- vs Standard-Dose Intravenous Magnesium for Acute Headache
Headache is one of the most common reasons for consultation in emergency departments and represents a significant cause of disability, particularly in patients with migraine and other primary headache disorders.
- Conditions
- Acute Headache, Migraine, Tension-type Headache, Cluster Headache
- Trial name
- MAGHEAD (NCT07779486)
- Testing
- Magnesium Sulfate 2 grams, Magnesium Sulfate 4 G, Paracetamol 1 g
- Where
- Tunisia
- Volunteers
- 300 people
- Sponsor
- University of Monastir
Episodic Migraine
Efficacy of Nerve Blocks for Episodic Migraine
The purpose of this study is to see how well blocking two to ten of the scalp nerves (that give feeling to the scalp and are painful during migraine headaches) with bupivacaine anesthetic (numbing medication) and low dose…
- Trial name
- NCT05734625
- Testing
- Bupivacaine HCl 0.5% Injectable Solution, Methylprednisolone 40 MG Injection
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Mayo Clinic
COVID-19, Long COVID
Effectiveness of Transcranial Direct Current in Patients With Persistent COVID-19 With Headaches and Chronic Pain.
This study aims to verify the efficacy/effectiveness of treatment with transcranial direct current stimulation (TDCS) in patients with Long Covid who experience headaches, migraines, and chronic pain, such as arthralgia and…
- Conditions
- COVID-19, Long COVID, Long Covid19, SARS CoV 2 Infection
- Trial name
- NCT05780450
- Testing
- Transcranial Direct Current Therapy (tDCS)
- Where
- 2 sites in Spain
- Volunteers
- 87 people
- Sponsor
- Fundación Universidad Católica de Valencia San Vicente Mártir
Vestibular Migraine, Dizziness
Chinese Real-world Study of Treatment of Vestibular Migraine
Vestibular migraine is a phenotype of migraine, characterized by more prominent vertigo symptoms compared to headache. Treatments for VM are mainly divided into two categories: acute treatment and preventive treatment.
- Conditions
- Vestibular Migraine, Dizziness, Vertigo
- Trial name
- NCT07203248
- Testing
- CGRP R Inhibitor; CGRP Inhibitor, none-CGRP
- Volunteers
- 2,000 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Migraine, Migraine Disease
Assessment of Oral Caffeine Intake in Changing the Severity of Acute Migraine Attack Using VAS Score Among Patients Attending Headache and Neurology Outpatients Clinic of Ainshams University Hospitals
Caffeine extracted from green tea to abort acute attack of Migraine
- Conditions
- Migraine, Migraine Disease, Migraine Headache, Migraine Headache, With or Without Aura
- Trial name
- NCT07022496
- Testing
- Caffeine (200 mg), triptans, NSAID (Nonsteroidal anti-inflammatory drugs)
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- Ain Shams University
Migraine, Tension-Type Headache
Carotid Sinus Massage in Trendelenburg Position for Headache Relief
Headaches significantly impact patients' quality of life, with tension-type headaches and migraines being among the most prevalent types.
- Trial name
- NCT06745648
- Testing
- Arm A - Carotid Sinus Massage + Trendelenburg (CSM+T)
- Where
- Argentina
- Volunteers
- 18 people
- Sponsor
- Hospital Municipal Pedro T. Orellana
Post-Acute COVID-19 Syndrome, ME/CFS
Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research
The unhide® Project is a non-interventional, longitudinal research study designed to establish a secure data repository of demographic, health, and lifestyle information from individuals with brain inflammation and related…
- Conditions
- Post-Acute COVID-19 Syndrome, ME/CFS, Rheumatic Arthritis, Juvenile Rheumatoid Arthritis (JRA)
- Trial name
- NCT04806620
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Brain Inflammation Collaborative
Pediatric Migraine
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.
- Trial name
- NCT04649242
- Testing
- Rimegepant/BHV3000
- Where
- 246 sites in United States, Canada and 7 more
- Volunteers
- 2,100 people
- Sponsor
- Pfizer
Vestibular Migraine
Acute Treatment of Vestibular Migraine by Rimegepant
To evaluate whether rimegepant improves acute vestibular symptoms and accompanying discomforts in patients with vestibular migraine.
- Trial name
- VM-rime (NCT07871097)
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Wensheng Qu
Migraine
Phase II Trial of PRT-064040 Nasal Spray for the Treatment of Migraine in Adults
The purpose of this study is to learn about the efficacy and safety of PRT-064040 Nasal Spray versus placebo in the acute treatment of moderate or severe migraine.
- Trial name
- NCT07304518
- Testing
- PRT-064040 nasal spray
- Where
- China
- Volunteers
- 456 people
- Sponsor
- Sichuan Purity Pharmaceutical Technology Co., Ltd.
Acute Treatment of Migraine
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to < 18 years of age).
- Trial name
- NCT04743141
- Testing
- Rimegepant (PF-07899801)
- Where
- 124 sites in United States, Poland and 1 more
- Volunteers
- 600 people
- Sponsor
- Pfizer
Migraine
Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients
This study is testing an investigational inhaled migraine medication to see how well it works, how safe it is, and how well people tolerate it.
- Trial name
- NCT07646613
- Testing
- ASY202
- Where
- 20 sites in United States
- Volunteers
- 108 people
- Sponsor
- Aspeya, Inc.
Migraine
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
This is a double-blind, randomized, multicenter, outpatient evaluation of the efficacy, safety, and tolerability of elismetrep, as compared with placebo, in the acute treatment of migraine.
- Trial name
- NCT07645924
- Testing
- Elismetrep
- Where
- 113 sites in United States
- Volunteers
- 1,800 people
- Sponsor
- TriGemX Bio, Inc.
Migraine
A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep, as compared with placebo, in the treatment of moderate or severe of migraine.
- Trial name
- NCT07816367
- Testing
- Elismetrep
- Where
- 72 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- TriGemX Bio, Inc.
Acute Treatment of Migraine
A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine
Acute treatments for migraine may not provide sufficient pain relief after an initial dose, and a second dose of a given medication may be needed to fully abort an attack.
- Trial name
- NCT07609914
- Testing
- Rimegepant
- Where
- 24 sites in United States, Israel
- Volunteers
- 400 people
- Sponsor
- Pfizer
Chronic Pain, Acute Pain
Assessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA
This study relies on the use of a smartphone application (SOMA) that the investigators developed for tracking daily mood, pain, and activity status in acute pain, chronic pain, and healthy controls over four months.The primary…
- Conditions
- Chronic Pain, Acute Pain, Post Operative Pain, Fibromyalgia, Primary
- Trial name
- NCT05754190
- Testing
- SOMA pain manager smartphone application
- Where
- United States
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Brown University
Episodic Migraine, Chronic Migraine
i-NEED: NEw migrainE Drugs Database
Approved by the Food and Drug Administration (FDA) and the European Medicine Agency (EMA) starting in 2018, anti-CGRP monoclonal antibodies (anti-CGRP mAbs) represent the first true revolution in the preventive treatment of…
- Conditions
- Episodic Migraine, Chronic Migraine, Medication Overuse Headache
- Trial name
- i-NEED (NCT07103694)
- Testing
- anti-CGRP monoclonal antibodies, gepants, combination of sumatriptan and naproxen
- Where
- 2 sites in Italy
- Volunteers
- 2,641 people
- Sponsor
- IRCCS San Raffaele Roma
Migraine, Migraine With Aura
Gepant treAtments: EffectIveNess and tolERability (GAINER)
The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of rimegepant as acute migraine treatment in a cohort of episodic or chronic migraine patients.
- Conditions
- Migraine, Migraine With Aura, Migraine Without Aura, Chronic Migraine
- Trial name
- GAINER (NCT05903027)
- Testing
- Rimegepant 75 MG Disintegrating Oral Tablet
- Where
- 2 sites in Italy
- Volunteers
- 100 people
- Sponsor
- University of Florence
Migraine
A Phase II Study of NB001 for Acute Migraine Treatment
The goal of this observational study is to Evaluate the Efficacy and Safety of NB001 for the Acute Treatment of Migraine in Adult patients diagnosed with migraine.
- Trial name
- Channel (NCT07577050)
- Testing
- Four tablets of NB001
- Volunteers
- 120 people
- Sponsor
- Chinese PLA General Hospital